Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer

NCT02724501 | Completed

• 2 other identifiers: UHN REB 01-0256-CTerry Fox Grant #11425
• Study Type: observational
• Target: 217
• Locations: 1 country
• Sites: 1

Brief Summary

This project seeks to understand the role of the PTEN tumour suppressor gene in endometrial cancer (tumours of the uterine lining), the most common gynecologic cancer in the developed world. The studies in this program span the spectrum from fruit flies to humans, as part of a synergistic partnership that will significantly enhance our understanding of the molecular genetic events involved in the development and progression of endometrial cancer. The discovery of new targets for therapy, and the ability to evaluate these in subsequent clinical trials is a significant strength of this scientific interaction, which may result in cures for patients with primary and relapse endometrial cancer and prevention of this cancer in women who are at high risk.

Conditions

Endometrial Neoplasms

Outcome Measures

Primary Outcomes (1)

• Number of endometrial cancer patients with inactivated PTEN tumor suppressor gene

  Determining the association of PTEN inactivation and PKB expression, mutation of p53, microsatellite instability and progesterone receptor status in endometrial cancer

  6 months

Interventions

questionnaire BEHAVIORAL

Using questionnaire to obtain patient's medical and family history of cancer.

Blood sample-DNA testing / Tumour-genetic markers PROCEDURE

Using Samples obtained to produce summary statistics on the tumour markers

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Endometrial Cancer

You may qualify if:

• Age 18 and older
• patients who had a hysterectomy
• patient able to provide consent and complete questionnaire

Sponsors & Collaborators

• University Health Network, Toronto: lead
• Canadian Cancer Trials Group: collaborator
• Princess Margaret Hospital, Canada: collaborator

Study Sites (1)

Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada

Location

MeSH Terms

Conditions

Endometrial Neoplasms

Interventions

Surveys and Questionnaires

Condition Hierarchy (Ancestors)

Uterine Neoplasms; Genital Neoplasms, Female; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Uterine Diseases; Genital Diseases, Female; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Genital Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Anthony Fyles, MD

  Princess Margaret Hospital, Canada

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 11, 2011
• First Posted: March 31, 2016
• Study Start: April 1, 2000
• Primary Completion: October 1, 2011
• Study Completion: October 1, 2011
• Last Updated: March 31, 2016

Record last verified: 2016-03

Locations

CA (1)